mAbs (Dec 2023)
10th antibody industrial symposium: new developments in antibody and adoptive cell therapies
- Ana Antunes,
- Luis Alvarez-Vallina,
- Federico Bertoglio,
- Nicolas Bouquin,
- Stéphanie Cornen,
- Francis Duffieux,
- Pierre Ferré,
- Raphaëlle Gillet,
- Christian Jorgensen,
- Mark B Leick,
- Bernard Maillère,
- Hélène Negre,
- Mireia Pelegrin,
- Nicolas Poirier,
- Dietmar Reusch,
- Bruno Robert,
- Guy Serre,
- Alain Vicari,
- Martin Villalba,
- Christoph Volpers,
- Gavin Vuddamalay,
- Hervé Watier,
- Thierry Wurch,
- Lennart Zabeau,
- Stefan Zielonka,
- Baolin Zhang,
- Alain Beck,
- Pierre Martineau
Affiliations
- Ana Antunes
- MabDesign, Lyon, France
- Luis Alvarez-Vallina
- Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain
- Federico Bertoglio
- Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Department of Biotechnology, Braunschweig, Germany, Current address
- Nicolas Bouquin
- REGIMBEAU, Paris – 69006 Lyon, France
- Stéphanie Cornen
- Innate Pharma, Marseille, France
- Francis Duffieux
- Large Molecules Research, Sanofi, Vitry-Sur-Seine, France
- Pierre Ferré
- Compugen Ltd, Holon, Israel
- Raphaëlle Gillet
- REGIMBEAU, Paris – 69006 Lyon, France
- Christian Jorgensen
- IRMB, université de Montpellier, Inserm U1183, Montpellier, France
- Mark B Leick
- Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA
- Bernard Maillère
- Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France
- Hélène Negre
- Institut de Recherches Internationales Servier, Suresnes, France
- Mireia Pelegrin
- IRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France
- Nicolas Poirier
- OSE Immunotherapeutics, Nantes, France
- Dietmar Reusch
- Pharma Technical Development Analytics Biologics, Roche Diagnostics GmbH, Penzberg, Germany
- Bruno Robert
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France
- Guy Serre
- Institut Toulousain des maladies infectieuses et inflammatoires - INFINITY- Inserm, CNRS, Université Toulouse III, Toulouse, France
- Alain Vicari
- Calypso Biotech SA, Plan-les-Ouates, Switzerland
- Martin Villalba
- IRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France
- Christoph Volpers
- Michalski Huettermann & Partner, Frankfurt/Main, Germany
- Gavin Vuddamalay
- MabDesign, Lyon, France
- Hervé Watier
- CEPR, INSERM U1100 Université de Tours, et CHU de Tours, Tours cedex, France
- Thierry Wurch
- Evotec, Toulouse, France
- Lennart Zabeau
- Orionis Biosciences BV, Ghent, Belgium
- Stefan Zielonka
- Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany
- Baolin Zhang
- Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
- Alain Beck
- Biologics CMC & Developability, Institut de Recherche Pierre Fabre, St Julien-en-Genevois Cedex, France
- Pierre Martineau
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France
- DOI
- https://doi.org/10.1080/19420862.2023.2211692
- Journal volume & issue
-
Vol. 15,
no. 1
Abstract
ABSTRACTThe annual “Antibody Industrial Symposium”, co-organized by LabEx MAbImprove and MabDesign, held its 10th anniversary edition in Montpellier, France, on June 28–29, 2022. The meeting focused on new results and concepts in antibody engineering (naked, mono- or multi-specific, conjugated to drugs or radioelements) and also on new cell-based therapies, such as chimeric antigenic receptor (CAR)-T cells. The symposium, which brought together scientists from academia and industry, also addressed issues concerning the production of these molecules and cells, and the necessary steps to ensure a strong intellectual property protection of these new molecules and approaches. These two days of exchanges allowed a rich discussion among the various actors in the field of therapeutic antibodies.
Keywords
- Antibody engineering
- Antibody industrial symposium
- antibody-related molecules
- biotherapeutics
- cell-based therapies
- congress
